In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on IntelGenx Technologies (IGXT), with a price target of $2. The company’s shares opened today at $0.61, close to its 52-week low of $0.43.
“IntelGenX announced FDA completed the pre-approval inspection (PAI) for Rizaport manufacturing at its Canadian-based facility. FDA made five observations which management believes can be addressed within the15 day time-frame.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.4% and a 29.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on IntelGenx Technologies is a Moderate Buy with an average price target of $1.75.
The company has a one-year high of $1.83 and a one-year low of $0.43. Currently, IntelGenx Technologies has an average volume of 400.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast.